| Ident. | Authors (with country if any) | Title |
|---|
| 000168 (2013) |
Olivier Rascol [France] | Physical exercise in Parkinson disease: Moving toward more robust evidence? |
| 000183 (2006) |
Olivier Rascol [France] | Defining a minimal clinically relevant difference for the unified Parkinson's rating scale: An important but still unmet need |
| 000193 (2004) |
Gilles Angibaud [France] ; Claude Gaultier [France] ; Olivier Rascol [France] | Atypical parkinsonism and Annonaceae consumption in New Caledonia |
| 000219 (1995) |
Jean-Louis Montastruc [France] ; Nelly Fabre [France] ; Olivier Blin [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; André Rascol [France] | Does fluoxetine aggravate Parkinson's disease? A pilot prospective study |
| 000418 (2004) |
Olivier Rascol [France] ; Atul Pathak [France] ; Haleh Bagheri [France] ; Jean-Louis Montastruc [France] | Dopaminagonists and fibrotic valvular heart disease: Further considerations |
| 000471 (1999) |
Erwan Bezard [France] ; Christine Brefel [France] ; Francois Tison [France] ; Helene Peyro-Saintpaul [France] ; Philippe Ladure [France] ; Olivier Rascol [France] ; Christian E. Gross [France] | Effect of the α2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey |
| 000645 (1997) |
Nathalie Andreu [France] ; Christine Damase-Michel [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Olivier Montastruc [France] | A dose‐ranging study of selegiline in patients with Parkinson's disease: Effect on platelet monoamine oxidase activity |
| 000792 (1992) |
Geneviève Durrieu [France] ; Marie-Elise Llau [France] ; Olivier Rascol [France] ; Jean-Michel Senard [France] ; André Rascol [France] ; Jean-Louis Montastruc [France] | Parkinson's disease and weight loss: A study with anthropometric and nutritional assessment |
| 000808 (2001) |
Jean-Louis Montastruc [France] ; Karine Desboeuf [France] ; Maryse Lapeyre-Mestre [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Christine Brefel-Courbon [France] | Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease |
| 000840 (2007) |
Joaquim Ferreira [Portugal] ; João Maia Silva [Portugal] ; Rita Freire [Portugal] ; João Pignatelli [Portugal] ; Leonor Correia Guedes [Portugal] ; Alexandra Feij [Portugal] ; Mário Miguel Rosa [Portugal] ; Miguel Coelho [Portugal] ; João Costa [Portugal] ; Ana Noronha [Portugal] ; Russell Hewett [Portugal] ; A. Marques Gomes [Portugal] ; J. L. Cirne De Castro [Portugal] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] | Skin cancers and precancerous lesions in Parkinson's disease patients |
| 000A64 (2010) |
Santiago Perez-Lloret [France] ; Emmanuelle Bondon-Guitton [France] ; Olivier Rascol [France] ; Jean-Louis Montastruc [France] | Adverse drug reactions to dopamine agonists: A comparative study in the french pharmacovigilance database |
| 000B78 (2012) |
Andrew Lees [Royaume-Uni] ; Stanley Fahn [États-Unis] ; Karla M. Eggert [Allemagne] ; Joseph Jankovic [États-Unis] ; Anthony Lang [Canada] ; Federico Micheli [Argentine] ; M. Maral Mouradian [États-Unis] ; Wolfgang H. Oertel [Allemagne] ; C. Warren Olanow [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Eduardo Tolosa [Espagne] ; David Squillacote [États-Unis] ; Dinesh Kumar [États-Unis] | Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease |
| 000D35 (1999) |
Jean-Louis Montastruc [France] ; Marc Ziegler [France] ; Olivier Rascol [France] ; Muriel Malbezin [France] | A randomized, double‐blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease |
| 000D43 (2010) |
Fabrizio Stocchi [Italie] ; Olivier Rascol [France] ; Karl Kieburtz [États-Unis] ; Werner Poewe [Autriche] ; Joseph Jankovic [États-Unis] ; Eduardo Tolosa [Espagne] ; Paulo Barone [Italie] ; Anthony E. Lang [Canada] ; C. Warren Olanow [Italie, États-Unis] | Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study |
| 000E29 (2004) |
Jan C. M. Zijlmans [Royaume-Uni, Pays-Bas] ; Berengere Debilly [France] ; Olivier Rascol [France] ; Andrew J. Lees [Royaume-Uni] ; Franck Durif [France] | Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study |
| 000F65 (1999) |
Jean Louis Montastruc [France] ; Olivier Rascol [France] ; Jean-Michel Senard [France] | Treatment of Parkinson's disease should begin with a dopamine agonist |
| 001072 (2003) |
Olivier Rascol [France] ; Pierre Payoux [France] ; Fabienne Ory [France] ; Joaquim J. Ferreira [France, Portugal] ; Christine Brefel-Courbon [France] ; Jean-Louis Montastruc [France] | Limitations of current Parkinson's disease therapy |
| 001085 (2005) |
Christine Brefel-Courbon [France] ; Pierre Payoux [France] ; Claire Thalamas [France] ; Fabienne Ory [France] ; Isabelle Quelven [France] ; François Chollet [France] ; Jean Louis Montastruc [France] ; Olivier Rascol [France] | Effect of levodopa on pain threshold in Parkinson's disease: A clinical and positron emission tomography study |
| 001118 (2013) |
Anthony E. Lang [Canada] ; Eldad Melamed [Israël] ; Werner Poewe [Autriche] ; Olivier Rascol [France] | Trial designs used to study neuroprotective therapy in Parkinson's disease |
| 001190 (2006) |
Olivier Rascol [France] ; Bruno Dubois [France] ; Alexandre Castro Caldas [Portugal] ; Stephen Senn [Royaume-Uni] ; Susanna Del Signore [France] ; Andrew Lees [Royaume-Uni] | Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study |
| 001262 (2006) |
Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni] | Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa |
